Src pY418 Antibody, anti-human, REAfinity™
Synonyms: ASV, SRC1, c-Src, p60-Src, pp60c-src
RECOMBINANT EXTENDED VALIDATION
Clone:
REA434 | K98-37
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for Src pY418 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-681, 130-106-739
Description:
Human Jurkat cells, either left unstimulated (right peak) or stimulated with 10 µM staurosporine for 2 hours at 37 °C, were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-Src pY418 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Extended validation for Src pY418 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA434
K98-37
high
SC1T2M3
high
QCRL-3
high
QCRL-1
low
QCRL-2
low

Cells were incubated with an excess of purified unconjugated Src pY418 (REA434) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for Src pY418 Antibody, anti-human, REAfinity™
Overview

Clone REA434 recognizes the human proto-oncogene tyrosine-protein kinase Src phosphorylated at tyrosine 418 (pY418). Src is a non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins, and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors, as well as cytokine receptors. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Src appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Src activity is regulated by phosphorylation at key sites, including the autophosphorylation site pY418 and the inhibitory site pY529.

Additional information: Clone REA434 displays negligible binding to Fc receptors.

Alternative names

ASV, SRC1, c-Src, p60-Src, pp60c-src

Detailed product information

Technical specifications

Clone
REA434
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, rat, other
Cross-reactivity
mouse, rat, chicken
Antigen
Src pY418
Molecular mass of antigen [kDa]
60, refers to canonical form
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2653508, AB_2653507, AB_2653505, AB_2653506

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Src pY418 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for Src pY418 Antibody, anti-human, REAfinity™
Publications
  1. Tanaka, A. et al. (1987) DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes. Mol. Cell. Biol. 7 (5): 1978-1983
  2. Roskoski, R. (2005) Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 331 (1): 1-14
  3. Wu, S. S. et al. (2005) Bombesin and angiotensin II rapidly stimulate Src phosphorylation at Tyr-418 in fibroblasts and intestinal epithelial cells through a PP2-insensitive pathway. Cell. Signal. 17 (1): 93-102